{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:50:55Z","timestamp":1755219055710,"version":"3.43.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Introduction and Importance<\/jats:title>\n            <jats:p>Dermatomyositis (DM) is an inflammatory myopathy with a known association with malignancies. The spectrum of associated cancers varies by age and geography, commonly including ovarian, lung, and breast cancers. However, its link with gestational trophoblastic neoplasia (GTN) has not been previously reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case Presentation<\/jats:title>\n            <jats:p>A 45-year-old woman with recently treated GTN presented with proximal muscle weakness, a facial rash, and elevated muscle enzymes. She was diagnosed clinically with DM and responded well to corticosteroids and methotrexate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Discussion<\/jats:title>\n            <jats:p>DM can occur before, during, or after cancer diagnosis. This rare case of DM following GTN supports the theory of immune cross-reactivity between tumor and muscle antigens. Diagnosis may rely on clinical criteria in resource-limited settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In patients with cancer who present with cutaneous manifestations and muscle symptoms, DM should be considered, irrespective of the cancer type or treatment status.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000003595","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:16:49Z","timestamp":1754497009000},"page":"5326-5329","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Dermatomyositis associated with gestational trophoblastic neoplasia: a case report"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6946-1847","authenticated-orcid":false,"given":"Ujjwol Prasad","family":"Risal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, B. P. Koirala Institute of Health Sciences, Dharan, Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"89\u201398","DOI":"10.1007\/s40257-015-0120-1","article-title":"Cancer risk in dermatomyositis: a meta-analysis of cohort studies","volume":"16","author":"Olazagasti","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar2987","article-title":"Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R3-20250806","first-page":"96\u2013100","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"R4-20250806","first-page":"2025","article-title":"Revised Surgical CAse REport (SCARE) guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Kerwan","year":"2025","journal-title":"Prem J Sci"},{"key":"R5-20250806","first-page":"322\u201328","article-title":"Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"845\u201352","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: a review","volume":"51","author":"Ashton","year":"2021","journal-title":"Intern Med J"},{"key":"R7-20250806","first-page":"2615\u201328","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"20\u201333","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and malignancy: a comprehensive review","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R9-20250806","first-page":"5960\u201368","article-title":"Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol Lett"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"1087\u201395","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s43046-023-00195-y","article-title":"Review of current literature on gestational trophoblastic neoplasia","volume":"35","author":"Shahzadi","year":"2023","journal-title":"J Egypt Natl Canc Inst"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"94\u201397","DOI":"10.1016\/j.ejca.2019.08.024","article-title":"Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia","volume":"121","author":"Choi","year":"2019","journal-title":"Eur J Cancer"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"2954\u201362","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"591\u2013601","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"25\u201328","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"196\u2013203","DOI":"10.1007\/s11926-996-0025-3","article-title":"Myositis specific autoantibodies","volume":"8","author":"Targoff","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"710\u201319","DOI":"10.1002\/1529-0131(199804)41:4<710::AID-ART19>3.0.CO;2-K","article-title":"Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy","volume":"41","author":"Rider","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s42003-021-01932-6","article-title":"Analysis of human total antibody repertoires in TIF1\u03b3 autoantibody positive dermatomyositis","volume":"4","author":"Megremis","year":"2021","journal-title":"Commun Biol"},{"key":"R19-20250806","doi-asserted-by":"crossref","first-page":"146\u201353","DOI":"10.1097\/PGP.0000000000000305","article-title":"PD-L1 expression in human placentas and gestational trophoblastic diseases","volume":"36","author":"Veras","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R20-20250806","doi-asserted-by":"crossref","first-page":"1544585","DOI":"10.3389\/fimmu.2025.1544585","article-title":"Immunotherapy in gestational trophoblastic neoplasia: advances and future directions","volume":"16","author":"Zeng","year":"2025","journal-title":"Front Immunol"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"1955\u201364","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:16:52Z","timestamp":1754497012000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003595","relation":{},"ISSN":["2049-0801"],"issn-type":[{"type":"electronic","value":"2049-0801"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"2025-04-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}